BioSpace News Archive

Notable Labs, Ltd. (Nasdaq: NTBL) (“Notable” or the “Company”) today presented the design for the PPMP-enabled Phase 2 trial with volasertib, in combination with decitabine, in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) at the American Association for Cancer Research (AACR 2024) being held in San Diego, CA (Poster abstract 5178).

Onchilles Pharma announced today the presentation of new preclinical data for systemically delivered N17465 in an oral presentation and tumor-directed N17350 in a poster presentation at the American Association for Cancer Research® (AACR) Annual Meeting 2024, taking place April 5 to 10 at the San Diego Convention Center.

According to Nova One Advisor, the global single-use bioprocessing market size was estimated at USD 28.45 billion in 2023 and it is projected to increase USD 128.24 billion by 2033 with a CAGR of 16.25% from 2024 to 2033.

According to Nova One Advisor, the global biomarkers market size was exhibited at USD 81.19 billion in 2023 and is projected to hit around USD 284.76 billion by 2033, growing at a CAGR of 13.37% during the forecast period 2024 to 2033.

QIAGEN N.V. announced plans to release results for the first quarter 2024.

According to Nova One Advisor, the global clinical trials market size was estimated at USD 81.90 billion in 2023 and it is projected to increase USD 153.59 billion by 2033 with a CAGR of 6.49% from 2024 to 2033.

MOLLI Surgical continues to push the boundaries of surgical care with the launch of OncoPen™, a minimally invasive surgical tool designed to empower surgeons and improve outcomes for patients affected with breast cancer.

Electrophysiologists at the Texas Cardiac Arrhythmia Institute (TCAI) at St. David’s Medical Center became the first in the nation to use a novel pulsed field ablation (PFA) system to treat patients with paroxysmal and persistent atrial fibrillation, a heart arrhythmia that affects millions of people worldwide, after receiving approval by the U.S. Food and Drug Administration.

SK Life Science, Inc. today announced the schedule for two oral and six poster presentations at the American Academy of Neurology (AAN) Annual Meeting taking place April 13–18, 2024, virtually and in-person in Denver, Colorado.

BioCity Biopharma today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for a Phase 1 study of BC2027.